 Vyant Bio Inc, a biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and Cyclica Inc, announced a non-exclusive strategic collaboration combining Vyant Bios patient-derived complex organoid biology alongside Cyclicas proteome-wide, Artificial Intelligence AI enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder CDD, a severe neurodevelopmental epilepsy disorder with no effective treatments or cure. Cherry Hill, New Jersey-based Vyants human-first approach to novel drug discovery incorporates patient biology into the earliest steps of the process with highly functional, disease-based neural organoids; while Cyclicas proprietary machine learning platforms marry knowledge and structure-based approaches to find novel targets, uncover new uses for existing drugs, and design new molecules with high potential. 